(2S,3R) -LP99

• Description:

  (2S,3R) -LP99 is a potent and selective BRD7 and BRD9 inhibitor with an KD of 99 nM for BRD9. (2S,3R) -LP99 inhibits the association of BRD7 and BRD9 to acetylated histones in vitro and in cells. (2S,3R) -LP99 demonstrates that BRD7/9 plays a role in regulating pro-inflammatory cytokine secretion[1].

• UNSPSC:

  12352005

• Target:

  Epigenetic Reader Domain

• Type:

  Reference compound

• Related Pathways:

  Epigenetics

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/2s-3r-lp99.html

• Purity:

  99.4

• Solubility:

  10 mM in DMSO

• Smiles:

  CC(CS(=O)(N[C@@H]([C@@H](N1C2=CC3=C(C(C)=CC(N3C)=O)C=C2)C4=CC=C(C=C4)Cl)CCC1=O)=O)C

• Molecular Formula:

  C26H30ClN3O4S

• Molecular Weight:

  516.05

• References & Citations:

  [1]Clark PG, et al. LP99: Discovery and Synthesis of the First Selective BRD7/9 Bromodomain Inhibitor. Angew Chem Int Ed Engl. 2015 May 18;54 (21) :6217-21.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  BRD7; BRD9

• CAS Number:

  [1808948-28-8]